Literature DB >> 16709822

Differential signaling of T cell generation of IL-4 by wild-type and short-deletion variant of type 2 G protein-coupled receptor for vasoactive intestinal peptide (VPAC2).

Mei-Chuan Huang1, Allison L Miller, Wengang Wang, Yvonne Kong, Sudhir Paul, Edward J Goetzl.   

Abstract

Vasoactive intestinal peptide (VIP) released from some neurons and T cells affects T cell migration, cytokine generation, and other functions by binding to constitutively expressed type 1 G protein-coupled receptor (VPAC1) or activation-induced type 2 G protein-coupled receptor (VPAC2). Recently, a short-deletion (SD) splice variant of mouse VPAC2 that lacks 14 amino acids at the end of the last transmembrane domain has been identified in T cells and shown to resemble wild-type (WT) VPAC2 in affinity of VIP binding but to differ by lack of signaling of T cell adenylyl cyclase, migration, and IL-2 secretion. As Th2 cells are the principal source of immune VIP and have the greatest functional responses to VIP, the differences in signals transduced by WT and SD VPAC2 were studied in VPAC2-low D10G4.1 model Th2 cell transfectants individually expressing the respective types of VPAC2 equally. WT and SD VPAC2 Th2 cell transfectants secreted equal amounts of VIP. WT VPAC2 transfectants generated more IL-4 than did SD VPAC2 transfectants, and this increment was dependent on endogenous VIP. Exogenous VIP further increased IL-4 production by WT VPAC2 transfectants but decreased IL-4 production by SD VPAC2 transfectants. Cotransfection of the two constructs diminished VIP enhancement of IL-4 production seen with WT VPAC2 alone by preventing increases in nuclear levels of the requisite transcription factors c-Maf and Jun B. Thus the ratio of two forms of T cell VPAC2 determines the net effect of VIP on IL-4 generation by activated Th2 cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16709822      PMCID: PMC1551935          DOI: 10.4049/jimmunol.176.11.6640

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  Regulation of VIP production and secretion by murine lymphocytes.

Authors:  C Martinez; M Delgado; C Abad; R P Gomariz; D Ganea; J Leceta
Journal:  J Neuroimmunol       Date:  1999-01-01       Impact factor: 3.478

2.  Cutting edge: is vasoactive intestinal peptide a type 2 cytokine?

Authors:  M Delgado; D Ganea
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

Review 3.  Vasoactive intestinal peptide mediation of development and functions of T lymphocytes.

Authors:  G Dorsam; J Voice; Y Kong; E J Goetzl
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

Review 4.  The significance of vasoactive intestinal peptide in immunomodulation.

Authors:  Mario Delgado; David Pozo; Doina Ganea
Journal:  Pharmacol Rev       Date:  2004-06       Impact factor: 25.468

Review 5.  Immunoeffector and immunoregulatory activities of vasoactive intestinal peptide.

Authors:  Julia K Voice; Glenn Dorsam; Robert C Chan; Carola Grinninger; Yvonne Kong; Edward J Goetzl
Journal:  Regul Pept       Date:  2002-11-15

6.  Allergic diathesis in transgenic mice with constitutive T cell expression of inducible vasoactive intestinal peptide receptor.

Authors:  J K Voice; G Dorsam; H Lee; Y Kong; E J Goetzl
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

7.  Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide.

Authors:  E J Goetzl; J K Voice; S Shen; G Dorsam; Y Kong; K M West; C F Morrison; A J Harmar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

8.  Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice.

Authors:  Julia K Voice; Carola Grinninger; Yvonne Kong; Yogesh Bangale; Sudhir Paul; Edward J Goetzl
Journal:  J Immunol       Date:  2003-01-01       Impact factor: 5.422

9.  VIP/PACAP preferentially attract Th2 effectors through differential regulation of chemokine production by dendritic cells.

Authors:  Mario Delgado; Elena Gonzalez-Rey; Doina Ganea
Journal:  FASEB J       Date:  2004-07-01       Impact factor: 5.191

10.  c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide.

Authors:  Julia Voice; Samantha Donnelly; Glenn Dorsam; Gregory Dolganov; Sudhir Paul; Edward J Goetzl
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

View more
  8 in total

Review 1.  Alternative splicing of G protein-coupled receptors: physiology and pathophysiology.

Authors:  Danijela Markovic; R A John Challiss
Journal:  Cell Mol Life Sci       Date:  2009-07-23       Impact factor: 9.261

Review 2.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

3.  Functional splice variants of the type II G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide in mouse and human lymphocytes.

Authors:  Allison L Miller; Deepti Verma; Carola Grinninger; Mei-Chuan Huang; Edward J Goetzl
Journal:  Ann N Y Acad Sci       Date:  2006-07       Impact factor: 5.691

Review 4.  Emerging neuropeptide targets in inflammation: NPY and VIP.

Authors:  Bindu Chandrasekharan; Behtash Ghazi Nezami; Shanthi Srinivasan
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-03-28       Impact factor: 4.052

5.  Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages.

Authors:  Juan Luis Herrera; Elena Gonzalez-Rey; Rafael Fernandez-Montesinos; Francisco J Quintana; Rafael Najmanovich; David Pozo
Journal:  J Cell Mol Med       Date:  2009-09       Impact factor: 5.310

6.  Modified BuShenYiQi formula alleviates experimental allergic asthma in mice by negative regulation of type 2 innate lymphoid cells and CD4+ type 9 helper T cells and the VIP-VPAC2 signalling pathway.

Authors:  Muhua Huang; Jinfeng Wu; Jingcheng Dong
Journal:  Pharm Biol       Date:  2021-12       Impact factor: 3.503

7.  Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype.

Authors:  M Barathova; M Takacova; T Holotnakova; A Gibadulinova; A Ohradanova; M Zatovicova; A Hulikova; J Kopacek; S Parkkila; C T Supuran; S Pastorekova; J Pastorek
Journal:  Br J Cancer       Date:  2007-11-20       Impact factor: 7.640

Review 8.  Regulatory Peptides in Asthma.

Authors:  Katarzyna Kaczyńska; Dominika Zając; Piotr Wojciechowski; Monika Jampolska
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.